DIRS.INFO The most relevant business & tech news

☆ UK investigates weight loss, diabetes drugs like Wegovy and Ozempic for suicide risks
▼ + stars: | 2023-07-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. U.K. health authorities on Wednesday said they are reviewing obesity and diabetes drugs like Novo Nordisk 's Wegovy and Ozempic after some patients who took the treatments reported thoughts of suicide or self-harm. The MHRA said the review includes all obesity and diabetes drugs available in the U.K. Aside from Ozempic and Wegovy, it includes Novo Nordisk's other weight loss drug Saxenda. Other diabetes drugs like AstraZeneca 's Bydureon, Eli Lilly 's Trulicity and Sanofi 's Lyxumia are also included in the probe. Novo Nordisk said in a statement that it received a review request from the MHRA on Monday.

Persons: MHRA, Eli Lilly, Sanofi Organizations: Novo Nordisk, Nordisk, Medicines, Healthcare, Agency, CNBC, European Union, AstraZeneca, Reuters Locations: Danish, U.S, Novo

☆ Weight loss drug Wegovy is from Europe — but users in the region face a long and costly wait
▼ + stars: | 2023-07-26 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +3 min

Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Still, it's seen as too expensive for many public health systems in Europe. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe. Eli Lily , whose diabetes drug Mounjaro can also be used for weight loss, has also faced supply gluts. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe," Field said.

Persons: Stefan Trumpf, it's, Emily Field, Wegovy's, Eli Lily Organizations: Novo Nordisk, Getty, CNBC, Denmark — Novo, Barclays, BMI, German Obesity Society, Novo Nordisk — Locations: Danish, Germany, Europe, Denmark, Norway, Novo, U.S

☆ European drugs regulator to review Wegovy, Ozempic following reports of suicidal thoughts
▼ + stars: | 2023-07-10 | by ( Anmar Frangoul | ) www.cnbc.com time to read: +1 min

The European Medicines Agency said Monday it would undertake a review into a number of drugs used to treat obesity and diabetes after it was reported some patients experienced thoughts of suicide or self-harm. "The review is being carried out in the context of a signal procedure raised by the Icelandic Medicines Agency following three case reports," the EMA said. The EMA said the case reports "included 2 cases of suicidal thoughts, one following the use of Saxenda and one after Ozempic. "The semaglutide-containing medicine Wegovy and the liraglutide-containing medicine Saxenda are authorised for weight loss, together with diet and physical activity," the EMA said. "Suicidal behaviour is not currently listed as a side effect in the EU product information of these medicines," the EMA said.

Organizations: Novo Nordisk, European Medicines Agency, Icelandic Medicines Agency, Saxenda Locations: Danish

☆ Ozempic is taking China by storm. Drugmakers are scrambling to boost supplies
▼ + stars: | 2023-06-06 | by ( Laura He | ) edition.cnn.com time to read: +5 min

Hong Kong CNN —Ozempic, originally a medication for treating diabetes, is in high demand worldwide with celebrities and social media users touting it as a miracle drug for weight loss. “This is a wonder drug,” according to a popular series of posts on Xiaohongshu, a Chinese social app similar to Instagram. Soaring pricesThe social media hype was so enormous that Xiaohongshu launched a crackdown in February and deleted more than 5,000 posts sharing weight loss experiences with Ozempic. Fill the shortageThe weight loss drug market in China is expected to boom in the coming years. Novo Nordisk has applied to China’s drug regulator to widen the scope of use for semaglutide, according to the National Medical Products Administration.

Persons: Hong Kong CNN — Ozempic, they’ve, ” Ozempic, Xiaohongshu, Ozempic, Kevin Frayer, hasn’t Organizations: Hong Kong CNN, Daily, First Affiliated, of Sun, University, Novo Nordisk, Tebon Securities, National Medical Products Administration, ., CNN, Huadong, Intellectual, Beijing Intellectual Property Locations: Hong Kong, China, Ozempic, Guangzhou, Shanghai, Hangzhou, Beijing

☆ Analysts say these 11 top-performing stocks are set to soar even more — giving one over 85% upside
▼ + stars: | 2023-05-18 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

The year is nearing its halfway mark, and global stocks have been doing much better than they had in volatile 2022. CNBC Pro screened for stocks that are beating the market nearly halfway into the year — and that analysts love. Only one stock had a 100% buy rating: Japan's Kansai Electric Power Company , a nuclear electric power generation firm. U.S. semiconductor firm Onsemi also made the screen, with analysts giving it 28% potential upside and a nearly 60% buy rating. Italian bank UniCredit had the highest potential upside in the list, at 85%, on top of a decent 88% buy rating.

☆ Wegovy Maker to Limit Starter-Dose Supplies in U.S. as Demand Surges
▼ + stars: | 2023-05-04 | by ( Dominic Chopping | ) www.wsj.com time to read: 1 min

Ozempic and Wegovy have become popular as treatments for weight management. Photo: JIM VONDRUSKA/REUTERSThe Danish pharmaceutical giant that makes the obesity drug Wegovy said it would temporarily hold back some lower-strength starter doses in the U.S. in an effort to safeguard supplies for current patients amid soaring demand. The Food and Drug Administration cleared Wegovy, made by Novo Nordisk , as a treatment for chronic weight management in 2021. It has since exploded in popularity.

☆ Why You Might Not Be Able to Start Taking Wegovy
▼ + stars: | 2023-05-04 | by ( Dominic Chopping | Peter Loftus | ) www.wsj.com time to read: 1 min

Some drugs initially approved to treat Type 2 diabetes are now being used for cosmetic weight loss. WSJ’s Daniela Hernandez explains how they work, their side effects, and concerns over unintended consequences. Illustration: Elizabeth SmelovThe Danish pharmaceutical giant that makes the obesity drug Wegovy said it would temporarily hold back some lower-strength starter doses in the U.S. in an effort to safeguard supplies for current patients amid soaring demand. The Food and Drug Administration cleared Wegovy, made by Novo Nordisk , as a treatment for chronic weight management in 2021. It has since exploded in popularity.

☆ Novo Nordisk cuts some U.S. supply of Wegovy obesity drug as demand soars
▼ + stars: | 2023-05-04 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +1 min

Danish pharmaceutical company Novo Nordisk said Thursday it was cutting the supply of starter doses of its obesity drug Wegovy in the U.S. as it struggles to keep up with surging demand. Novo Nordisk reported forecast-beating first-quarter sales Thursday following a spike in demand for its blockbuster weight-loss drug. Still, shares of the pharmaceutical giant were down 7% on Thursday morning on news of the supply cut. He added that there were further plans to increase production in the coming years. "This is also a reflection of a very big market and a very big unmet need for safe and efficacious medication, and that's where Wegovy comes in, being very efficacious and safe for patients [with obesity]," he said.

☆ Eli Lilly jumps to all-time highs on Alzheimer's news. Here's what it means our investment
▼ + stars: | 2023-04-21 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +6 min

LLY 1Y mountain Shares of Eli Lilly over the past 12 months. Still, a commercially successful Alzheimer's drug would be material for Eli Lilly and strengthen its long-term position. Mounjaro is the heart of our Eli Lilly investment case. Another catalyst looming for Eli Lilly shares is results from a study conducted by its competitor in the weight-loss category Novo Nordisk . Eli Lilly Pharmaceutical company logo SOPA Images | LightRocket | Getty Images

☆ U.S. Buyback Tax Could Hit More Foreign Firms Than First Expected
▼ + stars: | 2023-04-14 | by ( Jennifer Williams-Alvarez | ) www.wsj.com time to read: 1 min

Danish pharmaceutical company Novo Nordisk last month sent a comment letter to the Treasury Department objecting to two rules set out in December guidance on the 1% tax on stock buybacks. The U.S.’s new tax on stock buybacks has created a potential pain point for foreign companies: Those with stateside subsidiaries may find they are subject to the 1% levy on share repurchases. As initially written, the 1% tax on buybacks, which went into effect Jan. 1, would hit foreign companies in limited circumstances. Guidance from the government released in late December, however, changed expectations about the potential impact on foreign companies, stirring comment letters from businesses including Danish drugmaker Novo Nordisk A/S and groups representing multinational companies and global manufacturers.

☆ Credit Suisse upgrades Novo Nordisk on 'surprise' growth of obesity and diabetes drugs Ozempic and Wegovy
▼ + stars: | 2023-04-13 | by ( Michelle Fox | ) www.cnbc.com time to read: +2 min

Credit Suisse upgraded Danish pharmaceutical company Novo Nordisk to outperform from neutral on Thursday, citing growth in its obesity and diabetes drugs. "Rx trends for both Ozempic and Wegovy YTD have been a major surprise and have significantly outperformed our expectations," he wrote. Now that Wegovy is back in supply, Credit Suisse had expected a potential slowdown in growth for Ozempic. Instead, while there has been a rise in new patients taking Wegovy, Ozempic is continuing to see growth, Dunn said. "Novo sees growth being driven by penetration in diabetes rather than off-label obesity use, which is backed up by the fact the Ozempic growth has accelerated despite re-supply of Wegovy for Obesity," he said.

☆ Stocks making the biggest moves midday: Apple, Tesla, Netflix, Bed Bath & Beyond & more
▼ + stars: | 2023-04-13 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

The Wall Street firm anticipates U.S. retail sales could be down close to 20%. The Wall Street firm said growth in the drugs has "significantly outperformed" its expectations. Alibaba — Shares of the Chinese e-commerce giant rose 2%, rebounding from a near 6% selloff in the previous session. Chipotle — Shares rose 1% after Citi said it was optimistic about the restaurant chain's earnings report later this month. They will look for insight on whether Tesla is planning more price cuts on key models such as the Model 3 and Model Y.

☆ A flurry of news outside the portfolio has implications for 3 of our stocks
▼ + stars: | 2023-04-13 | by ( Jeff Marks | ) www.cnbc.com time to read: +7 min

Here are three noteworthy news developments over the past two days, which contain useful insights about our stocks. For the full year 2023, Novo now expects sales growth in the range of 24% and 30%, compared to prior estimates of 13% to 19%. In addition, operating profit growth is expected to be in the range of 28% and 34%, up from a prior range of 13% to 19%. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

☆ People taking obesity drugs Ozempic and Wegovy gain weight once they stop medication
▼ + stars: | 2023-03-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Patients taking blockbuster obesity drugs Ozempic or Wegovy will pack the pounds back on after they stop taking the medications. Studies have similarly shown weight rebound in people who stop taking Ozempic. So has Ozempic, which was first authorized to treat diabetes and is now being used off-label for weight loss. The shortage and other factors like out-of-pocket costs without insurance or unpleasant side effects have forced some people to stop taking Ozempic or Wegovy. Conde-Knape said so far data indicate that weight loss is maintained with long-term use of the drugs.

☆ As markets turn rocky, these global stocks look resilient and are expected to rally
▼ + stars: | 2023-03-15 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

Stocks slid, with the Dow Jones Industrial Average posting its fifth straight day of declines on Monday, while the 2-year Treasury yield tumbled . The screen threw up a mix of health care, consumer, utility and even some financial stocks. Canadian financial services firm Fairfax Financial Holdings and Japanese natural gas provider Tokyo Gas got among the highest expected earnings growth for this year – at more than 150% each. British bank HSBC also made it to the list, with nearly 50% expected earnings growth and 23% average upside. Italian luxury sports car maker Ferrari made the screen, with 21% expected earnings growth and around 20% upside.

☆ Bavarian Nordic to buy travel vaccine portfolio for up to $380 mln
▼ + stars: | 2023-02-15 | by ( ) www.reuters.com time to read: +1 min

Feb 15 (Reuters) - Danish pharmaceuticals company Bavarian Nordic (BAVA.CO) has agreed to buy a portfolio of travel vaccines from Emergent BioSolutions Inc (EBS.N) for up to $380 million, it said on Wednesday after delivering an upbeat outlook for 2023. The company said it would acquire a typhoid fever vaccine, one against cholera and a Chikungunya virus treatment that is in Phase III trials. Bavarian Nordics makes the only approved mpox vaccine and started receiving massive orders last year as the virus became a global issue. The company expects 2023 revenue of about 6 billion Danish crowns ($863 million) against the 3.15 billion crowns in preliminary 2022 results, with 4.4 billion crowns coming from mpox and smallpox vaccined contracts alone. Earnings before interest, tax, depreciation and amortisation (EBITDA) are expected to reach 2.2 billion crowns this year, up from 329 million crowns in the preliminary results for 2022.

☆ Market veteran says a new bull market is 'not far away' — and reveals how to play it
▼ + stars: | 2022-11-08 | by ( Zavier Ong | ) www.cnbc.com time to read: +2 min

The stock market has experienced a series of bear market rallies this year. Demmert said the bear market is now its "third and final phase." It is now in its 11 th month of a typical 12–15-month cycle, according to Demmert — indicating that a bottom could be close. "It's sort of an all-weather company at this point because they have the dominant exposure in that market globally. "That's where people go where they think it's safe, such as Google [parent Alphabet ] and Microsoft in the tech space.

Search resuls for: "Danish pharma"

17 mentions found